The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection), a radioactive diagnostic agent for prostate cancer detection.

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

TLX007-CDx is a cold kit designed for the preparation of PSMA-targeted PET imaging for prostate cancer. It leverages high-activity 68Ga sourced from advanced generators and cyclotrons, supported by ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate ...

Telix’s next-generation PSMA-PET imaging agent for prostate cancer, Gozellix receives US FDA approves: Melbourne, Australia Monday, March 24, 2025, 17:00 Hrs [IST] Telix, a biop ...

Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has approved its New Drug Application for Gozellix® gozetotide injection), Telix's next-generation ...

Some recommend scoring solid intraductal carcinoma as Gleason 5, but the cancer is linked to significantly poorer outcomes.

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK said it has given a world-first approval to Rotop's ...

for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive ...